Advertisement
ARCT vs EDIT
Which Stock Would AI Choose? Arcturus Therapeutics (ARCT) vs. Editas Medicine (EDIT) Stock Comparison
Key Takeaways
- Both ARCT and EDIT are clinical-stage biotech names that have sharply outperformed the broader market in 2026, despite both still posting net losses.
- Arcturus is an mRNA (messenger RNA) medicines company with a rare-disease pipeline and an approved COVID-19 vaccine; Editas is a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing company with no approved products.
- Editas has a clearer near-term clinical catalyst in EDIT-401, while Arcturus is advancing multiple mid-stage rare-disease programs and a Thermo Fisher manufacturing partnership.
- Both companies rely on collaboration revenue and maintain cash runways extending into 2027–2028.
- Sentiment around Arcturus has been supported by rising analyst price targets, while Editas has benefited from recent regulatory clearance for its first in-human trial.
Introduction
Investors screening the small-cap biotechnology sector often weigh companies with cutting-edge platforms but very different paths to value creation. ARCT (Arcturus Therapeutics) and EDIT (Editas Medicine) sit at the center of that debate: one is an mRNA medicines developer, the other a CRISPR gene-editing pioneer. Both trade at a fraction of their historical highs, both are unprofitable, and both have delivered strong 2026 relative performance. This stock comparison examines their business models, recent momentum, and market positioning for traders and long-term investors seeking to understand which profile may be better suited to current conditions.
ARCT Overview and Recent Performance
Arcturus Therapeutics Holdings is a San Diego–based mRNA medicines company focused on liver and respiratory rare-disease therapeutics. Its pipeline centers on ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency, a rare metabolic disorder, alongside its partnered KOSTAIVE self-amplifying mRNA COVID-19 vaccine. In recent weeks, the company reported interim Phase 2 data for ARCT-810 showing the therapy was generally safe and well-tolerated, and it unveiled LUNAR 2.0, a next-generation mRNA delivery platform. Arcturus also announced a collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032.
These catalysts have supported momentum. Shares have gained roughly 49% since the start of the year, and the consensus analyst price target has been revised upward. Revenue, however, remains thin: Arcturus reported about $2.96 million in quarterly revenue as legacy collaboration income rolled off, with cash and equivalents of roughly $191 million supporting a runway beyond 2028. The stock's relative performance reflects pipeline progress more than current earnings.
EDIT Overview and Recent Performance
Editas Medicine is a Cambridge, Massachusetts–based genome-editing company built on CRISPR/Cas9 technology. It currently has no approved products. After discontinuing its reni-cel program in late 2024 and reducing its workforce, Editas refocused on an in vivo (within-the-body) pipeline, with EDIT-401 as its lead candidate. EDIT-401 is an experimental, one-time gene-editing therapy designed to upregulate the LDL receptor to significantly lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH), an inherited disorder tied to cardiovascular risk.
In recent weeks, Editas received clearance to initiate its first-in-human Phase 1/2 STRIVE trial of EDIT-401 in Australia, a key de-risking milestone. The company reported a narrower-than-expected quarterly loss and roughly $211 million in cash, extending its runway into the second half of 2028. Shares have climbed more than 30% year to date, driven primarily by preclinical data and the clinical-clearance catalyst rather than fundamentals.
Trending AI Robots
For traders who prefer a systematic approach to stock selection, Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots. Tickeron maintains hundreds of AI Trading Bots that monitor thousands of tickers, yet only a small subset—selected from a larger library of 300+ bots—earns placement in this section based on current market conditions. These bots span a range of trading styles, strategies, timeframes, performance metrics, and ticker sets, with reported win rates across the broader library generally ranging from the high-60s to low-80s percent. Because no single bot fits every market environment, the trending selection is designed to surface the most suitable options at a given moment. Explore the Trending AI Robots page to review current selections and performance data.
Head-to-Head Comparison
The clearest contrast between the two companies is platform and stage. Arcturus has an approved vaccine product and multiple mid-stage rare-disease programs, giving it more clinical data points but also more operational complexity. Editas has narrowed to a single, focused lead candidate, EDIT-401, which concentrates its risk but also concentrates its potential catalyst into one readable clinical timeline.
On momentum, both stocks have benefited from strong 2026 sector tailwinds. Arcturus's gains have been supported by a steady stream of data readouts and a rising consensus price target, while Editas's move has been event-driven, led by the Australian trial clearance. Risk profiles differ: Editas faces binary clinical and competitive risk in the crowded cholesterol space, whereas Arcturus faces pipeline-execution and revenue-concentration risk as collaboration income declines. Both carry elevated beta and significant short interest relative to the broader market.
Tickeron AI Verdict
Based on observable trend consistency, catalyst clarity, and relative positioning, Tickeron's AI would likely lean slightly toward ARCT in the current environment. Arcturus combines a recently rising analyst price target, multiple concurrent clinical catalysts, and an established manufacturing partnership, which together suggest a broader support base for sustained trend continuation. Editas's near-term catalyst is more concentrated and its momentum more event-driven, which tends to produce higher volatility and less stable trends. That said, the distinction is narrow and probabilistic: a decisive positive EDIT-401 data readout could quickly shift relative positioning in EDIT's favor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and EDIT is a StrongBuy.
Momentum Indicator for ARCT turns positive, indicating new upward trend
ARCT saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 72 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARCT just turned positive on October 29, 2026. Looking at past instances where ARCT's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.825) is normal, around the industry mean (3.154). P/E Ratio (-3.312) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 68 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +22.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 180 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
EDIT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.895) is normal, around the industry mean (3.154). P/E Ratio (-4.045) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ARCT | EDIT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 36 | 44 | |
P/E GROWTH RATING 1..100 | 95 | 36 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARCT's Valuation (33) in the Pharmaceuticals Major industry is in the same range as EDIT (54) in the Biotechnology industry. This means that ARCT’s stock grew similarly to EDIT’s over the last 12 months.
ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EDIT (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to EDIT’s over the last 12 months.
ARCT's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as EDIT (99) in the Biotechnology industry. This means that ARCT’s stock grew similarly to EDIT’s over the last 12 months.
ARCT's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as EDIT (44) in the Biotechnology industry. This means that ARCT’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for ARCT (95) in the Pharmaceuticals Major industry. This means that EDIT’s stock grew somewhat faster than ARCT’s over the last 12 months.
| ARCT | EDIT | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 84% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 79% |
| Advances ODDS (%) | 3 days ago 82% | 4 days ago 80% |
| Declines ODDS (%) | 9 days ago 88% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARCT’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 0 green FA rating(s).
- ARCT’s FA Score: 1 green, 4 red.
- EDIT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARCT’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).
- ARCT’s TA Score: 4 bullish, 5 bearish.
- EDIT’s TA Score: 3 bullish, 5 bearish.
Price Growth
ARCT (@Biotechnology) experienced а +12.09% price change this week, while EDIT (@Biotechnology) price change was +11.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
ARCT is expected to report earnings on Nov 05, 2026.
EDIT is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARCT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.
| Ticker / NAME | Correlation To ARCT | 1D Price Change % | ||
|---|---|---|---|---|
| ARCT | 100% | -9.22% | ||
| ALEC - ARCT | 60% Loosely correlated | -1.34% | ||
| CRSP - ARCT | 51% Loosely correlated | -5.23% | ||
| EDIT - ARCT | 50% Loosely correlated | -8.87% | ||
| AXON - ARCT | 49% Loosely correlated | -2.35% | ||
| RXRX - ARCT | 46% Loosely correlated | -4.95% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DBND | 44.22 | 0.17 | +0.37% |
| DoubleLine Opportunistic Core Bond ETF (DBND) | |||
| DTRE | 41.59 | N/A | N/A |
| First Trust Alerian Disruptive Technology Real Estate ETF (DTRE) | |||
| AVDV | 105.11 | -1.72 | -1.61% |
| Avantis International Small Cap Value ETF (AVDV) | |||
| DBP | 86.48 | -3.49 | -3.88% |
| Invesco DB Precious Metals Fund (DBP) | |||
| APPX | 6.45 | -1.69 | -20.76% |
| Tradr 2X Long APP Daily ETF (APPX) | |||